CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY) Stock Short Interest Report for September

CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 976 shares, an increase of 1,218.9% from the September 15th total of 74 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 31,772 shares, the days-to-cover ratio is currently 0.0 days.

CochLear Price Performance

CochLear stock traded down $0.18 during midday trading on Friday, hitting $44.64. The company’s stock had a trading volume of 8,991 shares, compared to its average volume of 19,119. CochLear has a 1-year low of $31.82 and a 1-year high of $98.49. The company has a 50-day moving average price of $47.57 and a two-hundred day moving average price of $44.78.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on CHEOY shares. Canaccord Genuity Group cut CochLear from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 18th. Jefferies Financial Group lowered CochLear from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Zacks Research raised CochLear from a “strong sell” rating to a “hold” rating in a report on Monday, June 22nd. Finally, Royal Bank Of Canada downgraded CochLear from an “outperform” rating to a “sector perform” rating and set a $117.00 price target for the company. in a research note on Thursday, July 16th. Five equities research analysts have rated the stock with a Hold rating. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $117.00.

CochLear Company Profile

Cochlear Limited is an Australian medical technology company that develops, manufactures and supplies implantable hearing solutions for people with moderate to profound hearing loss. Its products are designed to help restore access to sound for individuals who may not benefit sufficiently from conventional hearing aids.

The company’s product portfolio includes cochlear implants, sound processors, bone-conduction hearing implants and related accessories and services. Cochlear also provides professional support, rehabilitation resources and connectivity solutions for recipients, hearing-health specialists and caregivers.

Founded in 1981 and headquartered in Sydney, Australia, Cochlear traces its origins to research led by Professor Graeme Clark, whose work contributed to the development of the world’s first multichannel cochlear implant.